Evicenter
P&T meetings

Emiltatug ledadotin (Emi-Le)

Adenoid cystic carcinoma with solid histology or high-grade transformation

Also known as XMT-1660
Manufacturer
Servier
Regulatory submission
Not announced
Launch
Not announced
Last updated
125 sources

Product information and disease descriptionProduct descriptionProduct information

Co-prescribed/Concomitant therapies

2 evidence topics · 2 sources

Renal-protective medications for proteinuria

“After a protocol amendment introduced an updated monitoring and management plan, including renal-protective medications, proteinuria-related dose reductions decreased from 38.9% to 20% and delays from 50.0% to 6.7% among patients with ACC.” (opens the source at this quote in a new tab)

Combination with immune checkpoint inhibitors: preclinical rationale

“Moreover, the combination of XMT-1660 and an immune checkpoint inhibitor may be beneficial to preclude a tumor's evasion of therapy by switching from expression of one antigen to the other. Particularly in this setting, the use of an antibody that does not block the immune-suppressive function of B7-H4 (Fig. 2A) may reduce the likelihood of exacerbating immune-related toxicity induced by the checkpoint inhibitor.” (opens the source at this quote in a new tab)

Clinical combination regimens

No evidence found.